Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies

BACKGROUND: Patients with cancer were excluded from phase 3 COVID-19 vaccine trials, and the immunogenicity and side effect profiles of these vaccines in this population is not well understood. Patients with cancer can be immunocompromised from chemotherapy, corticosteroids, or the cancer itself, wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Rouhani, Sherin Juliet, Yu, Jovian, Olson, Daniel, Zha, Yuanyuan, Pezeshk, Apameh, Cabanov, Alexandra, Pyzer, Athalia R, Trujillo, Jonathan, Derman, Benjamin A, O'Donnell, Peter, Jakubowiak, Andrzej, Kindler, Hedy L, Bestvina, Christine, Gajewski, Thomas F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9226983/
https://www.ncbi.nlm.nih.gov/pubmed/35732350
http://dx.doi.org/10.1136/jitc-2022-004766

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9226983/
https://www.ncbi.nlm.nih.gov/pubmed/35732350
http://dx.doi.org/10.1136/jitc-2022-004766

Ejemplares similares